[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-system-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-system-disease":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":41,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100598722","phase-1-a-study-to-evaluate-a-novel-gene-therapy-in-patients-with-relapsed-and-refractory-multiple-myeloma-100598722",false,"NCT07075185","A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma","A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma","inMMyCAR","Inclusion Criteria:\n\n* Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease\n* Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-directed monoclonal antibody\n* Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1\n* Participants must have acceptable laboratory values as defined by the protocol\n\nExclusion Criteria:\n\n* Participants must not have known central nervous system (CNS) involvement with myeloma\n* Participants cannot have plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, or primary light chain amyloidosis\n* Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy\n* Participants cannot require systemic steroids for any condition","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Multiple Myeloma in Relapse","Myeloma Multiple","Multiple Myeloma Progression","Neoplasms by Histologic Type","Neoplasm","Hemostatic Disorders","Vascular Disorder","Paraproteinemias","Blood Protein Disorders","Hematologic Disease and Disorders","Lymphoproliferative Disorders","Immunoproliferative Disorders","Immune System Disease","Gene Therapy",[42,43,44,45],"in vivo CAR-T","multiple myeloma","gene therapy","BMCA","RECRUITING","2026-04-22",{"date":49,"type":50},"2026-04-24","ACTUAL",{"date":52,"type":50},"2025-07-16",{"date":54,"type":21},"2042-05",{"name":56,"class":57},"Kelonia Therapeutics, Inc.","INDUSTRY",7,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":17,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100529082","detection-and-characterization-of-neurologic-manifestations-of-inborn-and-acquired-errors-of-immunity-100529082","NCT06169150","Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Aged \\>=2 years. To be seen at the NIH CC, participants must be \\>=3 years of age.\n2. Willing to allow specimens and data to be stored for future research.\n3. Willing to allow genetic testing on their biospecimens.\n4. Able to provide informed consent (for ages \\>=18 years) or has parent(s) or guardian(s) who can provide permission to participate on their behalf (for ages \\\u003C18 years).\n\n   * Decisionally impaired affected adult participants may have a legally authorized representative (LAR) to provide informed consent on their behalf.\n\nAdditional Inclusion Criterion for Affected Participants:\n\nHas a primary or acquired immunodeficiency and known or suspected infection or inflammation of the nervous system or post-infection sequelae, based on clinical or imaging data provided by the referral facility, or is at risk of developing such a neurologic complication. For the purpose of this study, neuroinfectious disease or neuroinflammation is defined as any of the following:\n\n1. Any neurologic symptoms accompanied by CSF with evidence of inflammation (which may include pleocytosis, hypoglycorrachia, elevated protein, or other evidence of intrathecal immune activation, including immunoglobulin \\[Ig\\] G index or presence of oligoclonal bands).\n2. Systemic infection or inflammatory disease with neurologic involvement.\n3. Neuroimaging suggestive of infection or inflammation (for example, presence of contrast-enhancing lesions on CT or MRI).\n4. Clinical presentation suggestive of infection or inflammatory process of the nervous system without better explanation.\n5. History of infection or inflammatory process of the nervous system.\n\nAffected participants must also have their own primary health care provider to manage their condition outside the NIH.\n\nAdditional Inclusion Criteria for Biological Relatives and Healthy Volunteers:\n\n1. Is either a biological relative of an affected participant or is unrelated.\n2. Does not have a known diagnosis of neuroinfectious disease or neuroinflammation.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Pregnant (for biological relatives and healthy volunteers).\n2. Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.",true,"2 Years","120 Years",{"count":69,"type":21},350,"OBSERVATIONAL","Background:\n\nImmune system and nervous system have significant interaction so that People with immunity diseases can have complications that affect the nervous system and people with some neurological disease may have defects in their immune system.These complications can affect many body functions, including how they move, walk, think, and feel. Researchers do not fully understand how immune diseases affect the nervous system. By learning more, they hope to create more effective treatments.\n\nObjective:\n\nTo learn more about the interaction between immune and nervous system and how immunity disease affect the nervous system.\n\nEligibility:\n\nPeople aged 2 years and older with an immunity disease. Their healthy biological relatives and other healthy volunteers are also needed.\n\nDesign:\n\nParticipants will be screened. Blood will be drawn for research. They may have imaging scans. Adults may undergo lumbar puncture: A needle will be inserted into their back to collect fluid from the space around the spinal cord. The imaging scans and lumbar puncture will be optional for healthy relatives and volunteers.\n\nAll participants will have 1 study visit per year for 5 years.\n\nThey will be asked to donate samples of body fluids at each visit. Blood samples are required for the study. All other donations are optional. These may include saliva, urine, breast milk, stool, vaginal secretions, and wound drainage.\n\nAffected participants may be asked for a skin biopsy: A small sample of skin will be removed. They may also be photographed or videotaped to record the symptoms of their disease.\n\nTests for each study visit may be spread over several days, if needed.\n\nVisits may be at the clinic. Participants may also collect their own samples at home and send them to the researchers....",[73,39],"Nervous System Disease",[75,76,77,78,79,80,81,82],"Errors Of Immunity","Neurological Diseases","Neuroinflammation","Neuroinfections","Neurodegeneration","Primary Immunodeficiency","Neuropathogenesis","Inborn Errors of Immunity","2025-09-24",{"date":85,"type":50},"2025-09-25",{"date":87,"type":50},"2024-01-12",{"date":89,"type":21},"2043-10-01",{"name":91,"class":92},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1]